Semaglutide research
What PubMed holds on Semaglutide, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.
- PubMed records
- 5,706
- Trial publications
- 341311 randomized
- Reviews
- 1698
- Human-subject tagged
- 3251
- Animal-only
- 273
- Clinical-trial publications 341
- Reviews 1,698
- Animal-only studies 273
- Other (in vitro, chemistry, commentary, unindexed) 3,394
Studies this site relies on
Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.
-
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Yang XD, Yang YY
This review encompasses all the pharmacokinetic data for subcutaneous and oral semaglutide in both healthy and diseased participants. The existing pharmacokinetic data can assist in developing and evaluating pharmacokinetic models of semaglutide and will help clinicians predict semaglutide dosages. In addition, it can also help optimize …
-
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino D, Abrahamsson N, Davies M, et al.
Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks.
-
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by …
-
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, et al.
One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and …
-
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey WT, Batterham RL, Bhatta M, et al.
In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430.
-
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).
-
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Jensen L, Helleberg H, Roffel A, et al.
Intact semaglutide in urine accounted for 3.1% of the administered dose in humans and less than 1% in rats; it was not detected in urine in monkeys. The metabolite profiles of semaglutide in humans appear to be similar to the profiles from the nonclinical species investigated.
-
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist
Hall S, Isaacs D, Clements JN
Semaglutide can be another acceptable option for patients with T2DM, and it has a potential role among patients who require weight loss with a low risk of hypoglycemia. This article evaluates the pharmacokinetics of semaglutide and summarizes its application to clinical practice based on efficacy and safety data.
Clinical-trial publications in PubMed
341 records carry PubMed’s clinical-trial publication type; the 40 most recent are listed. Tagging is done by NLM indexers and occasionally includes secondary analyses.
Newest records
The most recent PubMed additions for this query at the data-edition date, regardless of design.
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study Libyan J Med · 2026 · Primary study
- Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide Int J Qual Stud Health Well-being · 2026 · Primary study
- Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway Neuropharmacology · 2026 · Primary study
- ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations Spectrochim Acta A Mol Biomol Spectrosc · 2026 · Primary study
- Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty J Shoulder Elb Arthroplast · 2026 · Primary study
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications J Diabetes Metab Disord · 2026 · Review
- GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk N Am Spine Soc J · 2026 · Review
- Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort Clin Obes · 2026 · Primary study
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes J Diabetes Metab Disord · 2026 · Primary study
- Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program Am J Prev Cardiol · 2026 · Primary study